Tesamorelin, single vial

Growth hormone-releasing hormone (GHRH) analogue

Tesamorelin

Growth hormone-releasing hormone (GHRH) analogue. Supplied for laboratory research use only.

  • GHRH analogue; FDA-approved as Egrifta for HIV lipodystrophy only
  • EU marketing bid withdrawn in 2012 by the applicant
  • Bulk supplier cited for sterility violations, April 2026
  • Supplied for laboratory research use only. Not for human or veterinary use.
$239.99$359.97 Save 33%
Choose your supply
Most Popular
Best Value
In stock, ready to ship

90-Day Money-Back Guarantee

Every order is covered for ninety days from delivery. If you decide against it inside that window, contact us and we will refund the purchase price.

Research use only. Not for human or veterinary use or consumption. This product is not approved by the FDA and is not intended to diagnose, treat, cure or prevent any disease.

What it is
CompoundTesamorelin, also designated TH9507
ClassGrowth hormone-releasing hormone (GHRH) analogue
FormLyophilised powder, supplied in a vial
OriginatorTheratechnologies Inc.
Development status

Tesamorelin is approved by the FDA as a prescription medicine. FDA approved as Egrifta (Nov 2010) and the reformulated Egrifta SV (2019), specifically for reduction of excess abdominal fat in HIV-associated lipodystrophy — a narrow indication, not general fat loss. This product is not that medicine and is supplied for laboratory research use only.

Development status is stated above. No efficacy claim is made on this page.

Shipping & returns
ReturnsNinety days from delivery. Contact us and we will refund the purchase price.
Tesamorelin $239.99

The specifics

The details, if you want them.

DeveloperTheratechnologies Inc.
Development codeTH9507
ClassGHRH (growth hormone-releasing hormone) analogue
Amino acids44
Half-lifeapproximately 26 minutes
FormLyophilised powder (same physical form as the approved product)
Receptor target(s)GHRH receptor (growth hormone-releasing hormone receptor)
Binding mechanismN-terminal trans-3-hexenoic acid moiety conferring resistance to DPP-4 degradation

Development

Where it is up to.

Peer-reviewed and the basis for its narrow FDA approval. Its EU marketing application was withdrawn by the applicant; not approved in the EU, UK, or Australia.

Questions

The questions people actually ask.

What is tesamorelin?
A synthetic peptide developed by Theratechnologies, a growth hormone-releasing hormone (GHRH) analogue. This product is a research-only vial, not a prescription medicine.
Is this the same as Egrifta?
Tesamorelin is FDA-approved as Egrifta only for excess abdominal fat in HIV-associated lipodystrophy — not approved in the EU, UK, or Australia. This vial is a separate, unbranded research product.
What does "Research Use Only" mean?
Research Use Only means exactly that: intended for laboratory and research settings only, not for human or animal use, consumption, diagnosis, treatment, cure, or prevention of any disease.
How is this vial supplied?
As a vial of lyophilised (freeze-dried) powder, sold for laboratory and research use only.
What is your refund policy?
Ninety days from delivery. If you decide against it inside that window, contact hello@getmrpeps.com and we will refund the purchase price. Damaged or incorrect orders are replaced or refunded regardless.